Cited by 93Toxin Mechanisms and ImmunotoxinsCellular transport and secretionEndoplasmic Reticulum Stress and Disease

Ipomoeassin F Binds Sec61α to Inhibit Protein Translocation

Open access
Zong, Guanghui, Hu, Zhijian, O’Keefe, Sarah, Tranter, Dale, Iannotti, Michael J., Baron, Ludivine, Hall, Belinda, Corfield, Katherine +15 more·2019·Journal of the American Chemical Society

Published version of a preprint

Abstract

Ipomoeassin F is a potent natural cytotoxin that inhibits growth of many tumor cell lines with single-digit nanomolar potency. However, its biological and pharmacological properties have remained largely unexplored. Building upon our earlier achievements in total synthesis and medicinal chemistry, we used chemical proteomics to identify Sec61α (protein transport protein Sec61 subunit alpha isoform 1), the pore-forming subunit of the Sec61 protein translocon, as a direct binding partner of ipomoeassin F in living cells. The interaction is specific and strong enough to survive lysis conditions, enabling a biotin analogue of ipomoeassin F to pull down Sec61α from live cells, yet it is also reversible, as judged by several experiments including fluorescent streptavidin staining, delayed competition in affinity pulldown, and inhibition of TNF biogenesis after washout. Sec61α forms the central subunit of the ER protein translocation complex, and the binding of ipomoeassin F results in a substantial, yet selective, inhibition of protein translocation in vitro and a broad ranging inhibition of protein secretion in live cells. Lastly, the unique resistance profile demonstrated by specific amino acid single-point mutations in Sec61α provides compelling evidence that Sec61α is the primary molecular target of ipomoeassin F and strongly suggests that the binding of this natural product to Sec61α is distinctive. Therefore, ipomoeassin F represents the first plant-derived, carbohydrate-based member of a novel structural class that offers new opportunities to explore Sec61α function and to further investigate its potential as a therapeutic target for drug discovery.

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Integrity signals

Registry

Crossref · 10.1021/jacs.8b13506

Cites

62 of 62 references verified0 citation errors · 0 not checkable

Statistics

Claims the paper makes

The claims and statistics of this paper haven’t been checked yet.

Run the check — free, no account needed. It reads the open-access text and checks the sources it cites.

A few free checks a day · papers already verified open instantly · results are public

Claims other papers make about this one

Each is checked against this paper’s own text: does it say what the citing paper says it does?

  • Ipomoeassin F, eeyarestatin, and decatransin inhibit both the eukaryotic Sec61 complex and the bacterial SecYEG complex.

    “Components that inhibit both the eukaryotic Sec61 complex and the bacterial SecYEG complex are the glycoresin Ipomoeassin F (IpomF) (Zong et al., 2019; Steinberg et al., 2020), eeyarestatin (Cross et al., 2009; Steenhuis et al., 2021) and decatransin (Junne et al., 2015; Kalies and Römisch, 2015).”

    From The Dynamic SecYEG Translocon (2021) · cites this paper as Zong et al., 2019

  • IpomF inhibits SecYEG-dependent transport in vitro, but this requires significantly higher concentrations than required for inhibition of Sec61-dependent transport.

    “IpomF also inhibits SecYEG-dependent transport in vitro, but this requires significantly higher concentrations than required for inhibition of Sec61-dependent transport (Zong et al., 2019; Steinberg et al., 2020).”

    From The Dynamic SecYEG Translocon (2021) · cites this paper as Zong et al., 2019

Self-check

Percentages, sums and reported differences re-computed from the paper’s own numbers.

The self-check needs the paper’s full text.

Cites

Flagged first, then by citations

Cited by

Sorted by citations

Authors
Zong, G., Hu, Z., O’Keefe, S., Tranter, D., Iannotti, M. J., Baron, L., Hall, B., Corfield, K., Paatero, A. O., Henderson, M. J., Roboti, P., Zhou, J., Sun, X., Govindarajan, M., Rohde, J. M., Blanchard, N., Simmonds, R., Inglese, J., Du, Y., Demangel, C., High, S., Paavilainen, V. O., & Shi, W. Q.
Affiliations
  • University of Maryland, College Park (US)
  • University of Arkansas at Fayetteville (US)
  • University of Manchester (GB)
  • University of Helsinki (FI)
  • National Institutes of Health (US)
  • Inserm (FR)
  • University of Surrey (GB)
  • Baylor College of Medicine (US)
  • Emory University (US)
  • Centre National de la Recherche Scientifique (FR)
  • Ball State University (US)
Corresponding author
  • Simmonds, Rachel
  • Inglese, James
  • Du, Yuchun
  • Demangel, Caroline
  • High, Stephen
  • Paavilainen, Ville O.
  • Shi, Wei Q.
Venue
Journal of the American Chemical Society
Published
2019-05-06
Volume
141
Issue
21
Pages
8450-8461
ISSN
  • 0002-7863 (ISSN-L)
  • 1520-5126
OpenAlex
W2943937786
Cited by
93
References
62
Citations by year
2026: 7 · 2025: 13 · 2024: 13 · 2023: 18 · 2022: 11 · 2021: 18 · 2020: 11 · 2019: 2
FWCI
4.27
Type
journal article
Language
en
Open access
Locations
  • Journal of the American Chemical Society (publishedVersion, cc-by)
  • ChemRxiv (acceptedVersion, cc-by-nc-nd)
  • Europe PMC (PubMed Central) (publishedVersion)
  • PubMed Central (publishedVersion)
  • PubMed (publishedVersion)
  • Research Explorer (The University of Manchester) (publishedVersion, other-oa)
  • HAL (submittedVersion, other-oa)
  • Surrey Research Insight Open Access (The University of Surrey) (submittedVersion)
  • Royal College of Surgeons in Ireland (submittedVersion, cc-by-nc-nd)
  • Työväentutkimus Vuosikirja (submittedVersion)
Funders
  • National Institute of General Medical Sciences (P30 GM103450, R15 GM116032)
  • Wellcome Trust (202843/Z/16/Z, 204957/Z/16/Z)
  • National Center for Advancing Translational Sciences (1ZIA TR000048-03, ZIA TR000063-04)
  • University of Arkansas (NA)
  • Arkansas Biosciences Institute (NA)
  • Institut National de la Santé et de la Recherche Médicale (NA)
  • Suomen Akatemia (289737, 314672)
  • Institut Pasteur (NA)
  • Sigrid Juséliuksen Säätiö (NA)
  • Fondation Raoul Follereau (NA)
Topics
  • Life Sciences › Immunology and Microbiology › Immunology › Toxin Mechanisms and Immunotoxins
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Cellular transport and secretion
  • Life Sciences › Biochemistry, Genetics and Molecular Biology › Cell Biology › Endoplasmic Reticulum Stress and Disease
Keywords
Sec61α, endoplasmic reticulum, protein secretion, plant-derived natural products, chemoproteomics, molecular target identification, amino acid mutations, drug discovery targets
MeSH terms
SEC Translocation Channels, Binding Sites, Glycoconjugates, Humans, Molecular Structure, Protein Transport

About these checks

Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.

Statistics and arithmetic are recomputed, not judged.

Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.

What counts as a claim ›How we measure confidence ›How we check this ›

Are you an author, or do you see a problem with this page? Request a review